Skip to main content
OpenTrials
Completed

NCT Number: NCT03325335

Assessing the Effectiveness of Midazolam Premedication

Pre-anesthetic dosing of midazolam is commonly used in many hospitals for the induction of anesthesia, but the effect is still controversial. The purpose of this study was to evaluate the effectiveness of midazolam premedication in four aspects: anxiety reduction, pain relief, sedation and hemodynamic stability.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Pusan national university hospital

Busan, South Korea

About this study

Background

  • Midazolam premedication is a routine practice in many hospitals, but its efficacy remains controversial. We evaluated the effectiveness of midazolam premedication with respect to anxiety and sedation levels, hemodynamic parameters, and analgesic profiles.

Methods

  • Subjects
  • This randomized, prospective, open-label study was approved by IRB. After written informed consent, a total of 128 female patients aged between 20 and 65 years, ASA physical status Ⅰ or Ⅱ, scheduled for elective thyroidectomy were enrolled. Exclusion criteria were: central nervous system disorders, major cardiovascular disease, chronic pain disorders, peripheral neuropathy, diabetes mellitus neuropathy, nephropathy, hepatopathy, taking any medication affecting the central nervous system or heart rate, alcohol or drug abuse, pregnancy, and contraindication to midazolam premedication. Enrolled all subjects were randomly allocated to either midazolam premedication group (Group P, n=64) or control group (Group N, n=64). Patients of group P were premedicated with intramuscular glycopyrrolate 0.2mg and midazolam 0.05 mg/kg 30 minutes before surgery, while patients assigned to Group N were only received glycopyrrolate.
  • Anesthetic management
  • In the operating room, we did standard monitoring(ECG, pulse oximetry, noninvasive blood pressure, esophageal stethoscope temperature), train of four (TOF) and entropy and surgical pleth index(SPI). Target controlled infusion of propofol (4.0 μg/ml) and remifentanil (4 ng/ml) were used for induction of anesthesia based on the pharmacological models of Marsh and Minto, respectively. Intravenous rocuronium 1.0 mg/kg was administered for muscle relaxation. After intubation, propofol (3.0μg/ml) and remifentanil (2 ng/ml) were infused until incision time. 30 mg of ketorolac was administered 30 minutes before the end of the operation to control postoperative pain.
  • Assessment of response to midazolam
  • To evaluate the degree of anxiety, the Beck anxiety inventory was conducted at the preoperative day before surgery and immediately after arrival at the operating room. For analgesic profile assessment, SPI monitoring was performed in the operating room and NRS (numeric rating scale) measured in the recovery room and the general ward until the transition to oral analgesics. Also, additional medications for pain control were reviewed. Noninvasive blood pressure, heart rate, and entropy value were recorded at each measuring points in order to evaluate the hemodynamic stability and sedation level during anesthesia induction. Measuring points were initial time, prior to intubation, intubation, prior to incision and incision time. The time taken to induce anesthesia was also recorded.
  • Sample size and statistical analysis
  • In this study, sample size was determined based on Cohen's study. According to this analysis, when comparing the mean of two groups with α (significance criterion) = 0.05, β (probability of occurring type II error) = 0.2 and medium effect size (Cohen's d = 0.5), 64 subjects were needed per group.
  • After a normality test, continuous variables were analyzed with the use of an independent t-test, paired t-test, and repeated-measures ANOVA. Differences between categorical variables were calculated with the use of the chi-square test.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • American Society of Anesthesiologists physical status classification I or II
  • Scheduled for elective thyroidectomy under general anesthesia

Exclusion criteria

  • Central nervous system disorders
  • Major cardiovascular disease
  • Chronic pain disorders
  • Peripheral neuropathy
  • Diabetes mellitus neuropathy
  • Nephropathy
  • Hepatopathy
  • Taking any medication affecting the central nervous system or heart rate
  • Alcohol or drug abuse
  • Pregnancy
  • Contraindication to midazolam premedication

Treatment and study plan

midazolam premedication

Drug

Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.

Other names: Intramuscular midazolam

Remifentanil infusion

Drug

Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)

Other names: Target-controlled infusion (TCI) of remifentanil

Propofol infusion

Drug

Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)

Other names: Target-controlled infusion (TCI) of propofol

Primary outcomes

  1. Change in degree of anxiety

    Time frame: the anesthesiologist's visit on the day before surgery and pre-induction time after randomization

    Patients completed the Beck anxiety inventory (BAI) on two separate occasions, the anesthesiologist's visit on the day before surgery and pre-induction time after randomization. The BAI was a self-report questionnaire consisting of 21 questions.

  2. Change in sedation level

    Time frame: At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision

    Measuring the entropy value (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA).

  3. Change in noninvasive blood pressure (hemodynamic parameters 1)

    Time frame: At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision

    Measuring noninvasive blood pressure (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA)

  4. Change in SPI value (Analgesic profile 1)

    Time frame: At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision

    Measuring SPI (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA), which was calculated from the pulse oximetry wave

  5. Numeric rating scale (Analgesic profile 2)

    Time frame: Postoperative period (until transition to oral analgesics, up to 12 hours)

    Reviewing numeric rating scale (NRS) : 0 (No pain) ~ 10 (Worst possible pain)

  6. Analgesic requirement (Analgesic profile 3)

    Time frame: Postoperative period (until transition to oral analgesics, up to 12 hours)

    Reviewing additional medications for pain control

  7. Change in heart rate (hemodynamic parameters 2)

    Time frame: At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision

    Measuring heart rate (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA)

Secondary outcomes

  1. Procedure time of intubation

    Time frame: From the beginning of anesthesia to the completion of intubation

    Total time taken for intubation was recorded

  2. Correlation analysis between the SPI values and other parameters (heart rate, blood pressure, and entropy values)

    Time frame: At the time of pre-induction (initial), prior to intubation, intubation, prior to incision, and surgical incision

    Measuring SPI, noninvasive blood pressure, heart rate, and entropy values (CARESCAPE Monitor B850, GE Healthcare, Milwaukee, WI, USA)

Sponsors and collaborators

Lead sponsor

Pusan National University Hospital

Other

Registry information

Official study title

Randomized Controlled Trial Assessing the Effectiveness of Midazolam Premedication as an Anxiolytic, Analgesic, Sedative, and Hemodynamic Stabilizer

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Oct 30, 2017
Registry last updated
Oct 31, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.